<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21431917</article-id><article-id pub-id-type="pmc">3119331</article-id><article-id pub-id-type="publisher-id">1004</article-id><article-id pub-id-type="doi">10.1007/s00262-011-1004-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Verdegaal</surname><given-names>Els M. E.</given-names></name><address><phone>+31715264364</phone><fax>+31715266760</fax><email>e.verdegaal@lumc.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Visser</surname><given-names>Marten</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ramwadhdoeb&#x000e9;</surname><given-names>Tamara H.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>van der Minne</surname><given-names>Caroline E.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>van Steijn</surname><given-names>Jeanne A. Q. M. J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kapiteijn</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Haanen</surname><given-names>John B. A. G.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>van der Burg</surname><given-names>Sjoerd H.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Nortier</surname><given-names>Johan W. R.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Osanto</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Clinical Oncology, K-1-P, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2011</year></pub-date><volume>60</volume><issue>7</issue><fpage>953</fpage><lpage>963</lpage><history><date date-type="received"><day>6</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>5</day><month>3</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><abstract id="Abs1"><p>A phase I/II study was conducted to test the feasibility and safety of the adoptive transfer of tumor-reactive T cells and daily injections of interferon-alpha (IFN&#x003b1;) in metastatic melanoma patients with progressive disease. Autologous melanoma cell lines were established to generate tumor-specific T cells by autologous mixed lymphocyte tumor cell cultures using peripheral blood lymphocytes. Ten patients were treated with on average 259 (range 38&#x02013;474) million T cells per infusion to a maximum of six infusions, and clinical response was evaluated according to the response evaluation criteria in solid tumors (RECIST). Five patients showed clinical benefit from this treatment, including one complete regression, one partial response, and three patients with stable disease. No treatment-related serious adverse events were observed, except for the appearance of necrotic-like fingertips in one patient. An IFN&#x003b1;-related transient leucopenia was detected in 6 patients, including all responders. One responding patient displayed vitiligo. The infused T-cell batches consisted of tumor-reactive polyclonal CD8+ and/or CD4+ T cells. Clinical reactivity correlated with the functional properties of the infused tumor-specific T cells, including their in vitro expansion rate and the secretion of mainly Th1 cytokines as opposed to Th2 cytokines. Our study shows that relatively low doses of T cells and low-dose IFN&#x003b1; can lead to successful treatment of metastatic melanoma and reveals a number of parameters potentially associated with this success.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00262-011-1004-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Adoptive cell transfer</kwd><kwd>Melanoma</kwd><kwd>Tumor-specific T cells</kwd><kwd>IFN-alpha</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Melanoma has long been acknowledged to be a susceptible target for immunotherapy. A high number of melanomas are infiltrated by T cells, and the strength, phenotype, and activation status of infiltrated cells are associated with survival [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Adoptive cell transfer (ACT), i.e., the infusion of ex vivo expanded tumor-specific T cells, resulted in objective tumor responses in melanoma patients [<xref ref-type="bibr" rid="CR2">2</xref>]. Previous ACT trials have demonstrated that clinical success required lymphodepletion prior to T-cell infusion and concomitant administration of high-dose interleukin-2 (IL-2) to maintain cell proliferation and activation status [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>In allogeneic stem cell transplantation, interferon-alpha (IFN&#x003b1;) is routinely used to replace the far more toxic IL-2 to sustain the activation status of infused donor cells [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition, IFN&#x003b1; displays the capacity to upregulate HLA class I expression on tumor cells [<xref ref-type="bibr" rid="CR5">5</xref>]. These molecules are critical for tumor cell recognition by T cells and often (partially) downregulated in melanoma [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, IFN&#x003b1; is described to drive DC maturation required for generation of tumor-specific effector- and central-memory CD8+ T cells [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Therefore, we studied the feasibility and potential of ACT in combination with IFN&#x003b1; for the treatment of metastatic melanoma. Tumor-reactive T cells were obtained from PBMC, as highly effective melanoma reactive CTL are readily induced from PBMC [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] following stimulation with autologous tumor cells established from tumor biopsies.</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Melanoma patients</title><p>Patients with histologically proven cutaneous melanoma with verified progressive metastatic disease stage IV or unresectable stage III refractory to treatment before the start of the study and with at least one measurable target lesion were eligible for this phase I/II study. The protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center and conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent. Patients with brain metastases who are neurologically unstable and/or require use of dexamethasone and patients who are on continued chemo- or radiotherapy until 4&#x000a0;weeks before the start of IFN&#x003b1; injections were excluded from the study. The primary objective of this study was to investigate the feasibility and safety of adoptive T-cell transfer in combination with IFN&#x003b1;. Secondary endpoints include the best overall response defined as disease control (CR, PR, and SD) and evaluation of immunological parameters as predictors for response.</p></sec><sec id="Sec4"><title>Treatment protocol</title><p>Patients received T cells as three consecutive infusions of on average 259 (range 38&#x02013;474) million cells with a 3-week interval in combination with low-dose IFN&#x003b1; (3&#x000a0;million IU Roferon, Roche, Woerden, The Netherlands, subcutaneously daily) starting at day 7 before the first T-cell infusion and for a total of 12&#x000a0;weeks. Cryopreserved T cells were thawed and diluted to a total volume of 300&#x000a0;ml in PBS/2% human serum albumin (Albuman, Sanquin, Amsterdam, the Netherlands) and a final concentration of less than 1% DMSO. Then, the cells were administered intravenously over a time period of 30&#x02013;60&#x000a0;min. At various time points before, during and after treatment, the tumor response was assessed by physical examination and tumor imaging (CT and MRI) and evaluated according to the Response Evaluation Criteria in Solid Tumors 1.0 (RECIST) [<xref ref-type="bibr" rid="CR11">11</xref>] and according to the immune-related response criteria (irRC) [<xref ref-type="bibr" rid="CR12">12</xref>]. Toxicity was scored using the CTC scale version 3.0.</p></sec><sec id="Sec5"><title>Establishment of GMP-grade primary melanoma lines</title><p>Autologous melanoma cell lines were initiated and cultured using authorized Standard Operating Procedures (SOPs). Tumor tissue obtained by surgery was directly processed by mechanical dissociation and cultured in tumor medium consisting of Dulbecco&#x02019;s MEM (DMEM, Lonza, Veriers, Belgium) supplemented with 8% irradiated, heat-inactivated GMP-grade pre-tested FCS, penicillin (50&#x000a0;U/ml), streptomycin (50&#x000a0;&#x003bc;g/ml), and <sc>l</sc>-glutamine (4&#x000a0;mM) (all from Lonza). A stable cell line could be established (usually within 4&#x02013;12&#x000a0;weeks) for approximately 50% of the patients that was subsequently used as a stimulator line for the generation of tumor-reactive T-cell cultures. Before the initiation of T-cell cultures, the melanoma origin of the used autologous tumor cells was confirmed by RT&#x02013;PCR [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>] and they were shown to express at least three of the eleven melanoma-associated antigens studied (data not shown).</p><p>Furthermore, genotyping of HLA alleles was performed in all melanoma cell lines and corresponding PBMC to confirm their origin and revealed in addition that none of the used melanoma cell lines showed complete or partial genetic loss of HLA alleles. In addition, the surface expression of HLA class I and class II molecules was assessed by flow cytometry using Alexa-648-conjugated W6/32 HLA class I A/B/C (Serotec, Dusseldorf, Germany) and FITC-conjugated Bu26 HLA-DR/DP/DQ-specific antibodies (Bio-connect, Huissen, the Netherlands). The samples were measured on a FACSCalibur and analyzed using CellQuest Software and showed that HLA class I surface expression was not downregulated on the cell lines used for the induction of T cells and that all IFN&#x003b3;-stimulated melanoma cells, except Mel AB and Mel CT, displayed variable surface expression of HLA class II (data not shown).</p></sec><sec id="Sec6"><title>Generation and release of T-cell batches for infusion</title><p>Tumor-reactive T cells were cultured using a mixed lymphocyte tumor cell culture (MLTC) as described [<xref ref-type="bibr" rid="CR21">21</xref>]. Briefly, PBMC were isolated from heparinized venous blood and cryopreserved until use. Approximately 50 million PBMC were thawed, washed, counted and resuspended (1&#x02013;2&#x000a0;&#x000d7;&#x000a0;10e<sup>6</sup>&#x000a0;cells per ml) in T-cell medium; Iscoves MDM (Lonza) supplemented with 8% heat-inactivated pooled human serum (Sanquin Bloodbank, Dordrecht, The Netherlands), penicillin (50&#x000a0;U/ml), streptomycin (50 &#x003bc;g/ml), and <sc>l</sc>-glutamine (4&#x000a0;mM) (all GMP-grade from Lonza) and plated 1&#x000a0;ml per well in a 24-well culture plate. Next, autologous tumor cells were lethally irradiated (100&#x000a0;Gy) and resuspended (1&#x000a0;&#x000d7;&#x000a0;10e<sup>5</sup>&#x000a0;cells per ml) in T-cell medium. One milliliter of this tumor cell suspension was added per well containing PBMC. Human recombinant IL-4 (5&#x000a0;ng/ml, Cellgenix, Sieversen, Germany and Gentaur, Brussels Belgium) was added at day 0. Starting from day 2, low-dose (150&#x000a0;IU/ml) IL-2 (Aldesleukin, Novartis, Arnhem, The Netherlands) was added. Culture medium containing IL-2 was refreshed every 2&#x02013;3&#x000a0;days. The T cells were cultured for a total of 4&#x000a0;weeks and stimulated weekly with irradiated tumor cells as described above. After 4&#x000a0;weeks of culture, the T-cell batches were evaluated for sterility, phenotype, and tumor reactivity before they were released for infusion. Phenotypic analysis was performed using a FACSCalibur and CellQuest software (BD Pharmingen, San Jose, CA, USA). T cells were released when they consist of more than 80% of T cells (CD3+CD4+ and CD3+CD8+) or NK cells (CD3-CD56+) (All conjugated-mAb were from BD Pharmingen except CD8-APC from DAKO, Heverlee, Belgium). In addition, the frequency of Treg CD4+CD25+FoxP3+ T cells was evaluated in the T-cell batches using CD4-APC and CD25-FITC mAb (both from BD Pharmingen) in combination with the human Treg/FoxP3-PE staining kit (eBiosciences, Vienna, Austria). Tumor reactivity was assessed by a <sup>51</sup>Cr-cytotoxicity assay [<xref ref-type="bibr" rid="CR22">22</xref>], and in order to be released for infusion, T cells were required to specifically lyse autologous tumor cells but not autologous EBV-LCL or PHA blasts (difference &#x0003e;10% at an E/T ratio of 30). Alternatively, tumor reactivity was assessed by IFN&#x003b3; ELISA (Sanquin, Amsterdam, The Netherlands) where T-cell batches were required to secrete &#x0003e;200&#x000a0;pg/ml IFN&#x003b3; in response to autologous tumor cells and at least twice the amount induced by the negative controls, i.e., autologous EBV-LCL or PHA blasts [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec7"><title>Analysis of T-cell specificity, polyclonality, and cytokine secretion by multiparameter flow cytometry</title><p>To examine T-cell reactivity, 0.5&#x02013;1&#x000a0;&#x000d7;&#x000a0;10e<sup>6</sup> T cells were seeded in a 24-well plate in T-cell medium and stimulated with 0.5&#x02013;1&#x000a0;&#x000d7;&#x000a0;10e<sup>6</sup> autologous melanoma cells. After 1&#x000a0;h, Brefeldin-A (10&#x000a0;&#x003bc;g/ml) was added and stimulation was continued overnight. The next day T cells were harvested, and part of the cells were stained with a mix of antibodies to CD154-PECy5, CD137-APC, CD4-PECy7, CD8-APCCy7, IFN&#x003b3;-FITC, and IL-2-PE (all from BD Pharmingen) and CD3-Pacific Blue (DAKO) see [<xref ref-type="bibr" rid="CR24">24</xref>]. Non-stimulated T cells or T cells stimulated with PHA (5&#x000a0;&#x003bc;g/ml) served as controls. Responses were considered positive when the percentage of tumor-stimulated CD154+ and/or CD137+ T cells was at least three times the medium control (see Fig&#x000a0;1. of the on-line available supplementary materials).</p><p>Polyclonality of the T-cell batches was evaluated by the anti-IFN&#x003b3;-FITC and IL-2-PE Ab by either one of the 8 different mixes of FITC- and/or PE-conjugated anti-TCRV&#x003b2; mAb (BETAmark, Beckman Coulter) as previously described [<xref ref-type="bibr" rid="CR25">25</xref>]. The different T-cell clones were operationally defined as the percentage of activated tumor-specific CD4+ or CD8+ T cells expressing the same TCRV&#x003b2;-chain, within the population of tumor-specifically activated CD154+ and/or CD137+ T cells, respectively. All samples were measured on a calibrated LSRII and analyzed using DIVA software (BD). A TCRV&#x003b2; was considered dominant (&#x0003e;10%), subdominant (3&#x02013;10%), or minor (&#x0003c;3%) based on the percentage of tumor-specific cells using the same TCRV&#x003b2; [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>In parallel, T cells were stimulated with autologous melanoma cell lines in the absence of Brefeldin-A, and supernatant was harvested after 24&#x000a0;h in order to analyze the cytokine secretion using the human Th1/Th2 cytometric bead array (BD Pharmingen). T cells stimulated with PHA (5&#x000a0;&#x003bc;g/ml), medium alone, and autologous EBV-LCL or PHA blasts were included as controls. Antigen-specific cytokine production was defined by a cytokine concentration above the cut-off value (IFN&#x003b3; 50&#x000a0;pg/ml; other cytokines 10&#x000a0;pg/ml) and &#x0003e;2&#x000a0;&#x000d7;&#x000a0;the concentration of the medium control [<xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="Sec8"><title>Statistics</title><p>The overall survival was analyzed using Kaplan&#x02013;Meier and SPSS version 2.0. The Cox regression could not performed due to the low patient number, and therefore no confidence interval and hazard ratio could be provided. Post hoc statistical analyses were performed to determine potential correlates with clinical responsiveness using the non-parametric Mann&#x02013;Whitney Test or Wilcoxon Signed Ranks Test. All p values are two-sided and are considered significant when they are less than 0.05.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Patient characteristics</title><p>Ten patients with metastatic melanoma were treated with adoptive transfer of tumor-reactive T cells (ACT) in combination with low-dose IFN&#x003b1;. Two additional patients were not treated although we obtained tumor-specific T cells, because they continued using chemotherapy or required dexamethasone to control brain metastasis-related edema, respectively, and therefore had to be taken of study. The characteristics of the ten treated patients are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. All patients had stage IV melanoma with visceral metastases, including liver, spleen, soft tissue, or bone metastases, in addition to metastasis in lymph nodes, lungs, or skin. Prior to ACT, all but one patient (GM) were treated with radiotherapy and/or chemotherapy (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) and had progressive disease (PD) refractory to treatment. Seven out of ten patients had brain metastasis (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Patients FB and GM had high levels of serum LDH (&#x0003e;2&#x000a0;&#x000d7;&#x000a0;upper normal limit (UNL)) correlating with a bad prognosis and high tumor load before the start of T-cell infusions, and patient CT had elevated LDH (i.e., &#x0003e;UNL but &#x0003c;2&#x000a0;&#x000d7;&#x000a0;UNL). Eight patients completed at least one infusion cycle.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient ID</th><th align="left">Age/sex</th><th align="left">Status before therapy</th><th align="left">Lesion sites<sup>a</sup></th><th align="left">LDH<sup>b</sup></th><th align="left">Prior therapy<sup>c</sup></th><th align="left">Infused cells (&#x000d7;10<sup>8</sup>)</th><th align="left">Best overall response RECIST<sup>d</sup></th><th align="left">Duration/disease stabilization (mo)</th><th align="left">Best overall response IrRC<sup>e</sup></th><th align="left">Duration/disease stabilization (mo)</th><th char="." align="left">Overall survival (mo)</th></tr></thead><tbody><tr><td align="left">AB</td><td align="left">42/m</td><td align="left">PD</td><td align="left">Li</td><td align="left">Normal</td><td align="left">RT</td><td char="." align="char">19.1</td><td align="left">SD</td><td align="left">3</td><td align="left">iSD</td><td align="left">6</td><td char="." align="char">47+</td></tr><tr><td align="left">BO</td><td align="left">35/m</td><td align="left">PD</td><td align="left">L, SC, LN, B</td><td align="left">Normal</td><td align="left">CT, RT</td><td char="." align="char">14.4</td><td align="left">CR</td><td align="left">45+</td><td align="left">iCR</td><td align="left">45+</td><td char="." align="char">51+</td></tr><tr><td align="left">CT</td><td align="left">73/f</td><td align="left">PD</td><td align="left">Spl, Bo</td><td align="left">Elevated</td><td align="left">RT</td><td char="." align="char">14.2</td><td align="left">SD</td><td align="left">3</td><td align="left">iSD</td><td align="left">3</td><td char="." align="char">15</td></tr><tr><td align="left">DK</td><td align="left">43/m</td><td align="left">PD</td><td align="left">L, SC.LN, B</td><td align="left">Normal</td><td align="left">CT, RT</td><td char="." align="char">22.5</td><td align="left">PR</td><td align="left">16+</td><td align="left">iPR</td><td align="left">16+</td><td char="." align="char">22+</td></tr><tr><td align="left">EN</td><td align="left">49/f</td><td align="left">PD</td><td align="left">B, SC/ID</td><td align="left">Normal</td><td align="left">CT</td><td char="." align="char">16.9</td><td align="left">SD</td><td align="left">3+</td><td align="left">iSD</td><td align="left">3+</td><td char="." align="char">8+</td></tr><tr><td align="left">FB</td><td align="left">44/f</td><td align="left">PD</td><td align="left">Ad, LN, B</td><td align="left">High</td><td align="left">CT, RT</td><td char="." align="char">1.4</td><td align="left">PD</td><td align="left">n.a.</td><td align="left">iPD</td><td align="left">n.a.</td><td char="." align="char">1</td></tr><tr><td align="left">GM</td><td align="left">56/f</td><td align="left">PD</td><td align="left">Bo, Li, LN, B Lu</td><td align="left">High</td><td align="left">&#x02013;</td><td char="." align="char">2.0</td><td align="left">PD</td><td align="left">n.a.</td><td align="left">iPD</td><td align="left">n.a.</td><td char="." align="char">1.5</td></tr><tr><td align="left">HL</td><td align="left">55/m</td><td align="left">PD</td><td align="left">Lu, Mu</td><td align="left">Normal</td><td align="left">CT</td><td char="." align="char">10.6</td><td align="left">PD</td><td align="left">n.a.</td><td align="left">iPD</td><td align="left">n.a.</td><td char="." align="char">15+</td></tr><tr><td align="left">IV</td><td align="left">57/m</td><td align="left">PD</td><td align="left">B</td><td align="left">Normal</td><td align="left">RT</td><td char="." align="char">6.3</td><td align="left">PD</td><td align="left">n.a.</td><td align="left">iPD</td><td align="left">n.a.</td><td char="." align="char">3</td></tr><tr><td align="left">JS</td><td align="left">68/m</td><td align="left">PD</td><td align="left">B, LN, Lu</td><td align="left">Normal</td><td align="left">CT, RT</td><td char="." align="char">3.9</td><td align="left">PD</td><td align="left">n.a.</td><td align="left">iPD</td><td align="left">n.a.</td><td char="." align="char">3</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Metastatic sites at the start of T-cell treatment include lung (Lu), brain (B), subcutaneous (SC), lymph node (LN), liver (Li), muscle (Mu), adrenal (Ad), spleen (Sp), and bone (Bo) metastasis</p><p><sup>b</sup>Serum LDH concentration was considered high when it was more than twice the upper limit and elevated when it was above but less then twice the upper limit</p><p><sup>c</sup>Prior treatments include radiotherapy (RT) and chemotherapy (CT)</p><p><sup>d</sup>Best overall response according to response criteria in solid tumors (RECIST 1.0)</p><p><sup>e</sup>Best overall response according to immune-related response criteria (irRC)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Clinical response</title><p>An objective clinical response was observed in two out of ten patients according to irRC and RECIST, and in three additional patients, clinical benefit was manifested as SD. One patient (BO) exhibits an ongoing complete response with duration of more than 45&#x000a0;months that was established after two cycles of ACT (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Notably, this patient had an incompletely resected brain metastasis that completely disappeared after treatment. A second patient (DK) displayed an ongoing PR with complete regression of all but one mesenterial lesion, including a brain lesion, 4 skin lesions, and 4 LN-lesions. Two patients (EN, see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a, and CT) showed SD (durations of 3+ and 3&#x000a0;months, respectively) but the latter received only one infusion cycle since treatment had to be discontinued due to a SAE. One other patient (AB) showed SD with duration of 6&#x000a0;months when evaluated according to irRC, whereas the duration was 3&#x000a0;month according to RECIST. However, this patient progressed very slowly resulting in an unexpected long survival (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Non-responders were defined as patients with PD by evaluation of CT and MRI scans according to RECIST and irRC or by death due to PD.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Clinical response. <bold>a</bold> ACT-induced regression of metastatic lesions before (<italic>upper panels</italic>) and after (<italic>lower panels</italic>) T-cell infusions. CT scans showing complete regression of two lung lesions obtained 6&#x000a0;month after T-cell infusion in the CR patient <italic>BO</italic> are depicted in the <italic>left two panels</italic>. Regression of a subcutaneous lesion obtained 3&#x000a0;months after start of the infusions in patient <italic>EN</italic> is depicted in the <italic>right panel</italic>. <bold>b</bold> Kaplan&#x02013;Meier plot comparing the overall survival of the responder and non-responder patients. <bold>c</bold> IFN&#x003b1; treatment induced a mild leucopenia. From day 7 before infusion of the first T-cell dose, patients were treated with 3.10e6 U IFN&#x003b1; s.c daily for a total of 12&#x000a0;weeks. The absolute leukocyte count (x10e9/L) measured 1&#x000a0;week after the start of IFN&#x003b1; injections (i.e., day 0) is depicted. The values measured before treatment are shown as a <italic>black arrowhead</italic>. Absolute leukocyte counts of the responder patients are depicted as <italic>filled bars</italic> and those of the non-responders as <italic>open bars</italic>. The best overall clinical response of the individual patients is given in <italic>brackets</italic> behind the patient ID. Normal leukocyte counts range between 4 and 12 as is indicated by the <italic>light gray area</italic>. <bold>d</bold> The percentage reduction in peripheral neutrophil counts obtained after 7&#x000a0;days of IFN&#x003b1; treatment (i.e., day 0) of the non-responder (<italic>open circles</italic>) and responder (<italic>closed circles</italic>) patients correlates with their overall survival</p></caption><graphic xlink:href="262_2011_1004_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec12"><title>Adverse events</title><p>In half of the patients (5/10), fever (grade 1) was observed up to 20&#x000a0;h and one patient displayed transient hypertension (grade 1) after T-cell infusion. No other adverse symptoms were observed immediately after infusion.</p><p>Five out of ten patients suffered from grade 1 (<italic>n</italic>&#x000a0;=&#x000a0;4) to grade 2 (<italic>n</italic>&#x000a0;=&#x000a0;1) psychological symptoms associated with the administration of IFN&#x003b1; (Roferon), resulting in the reduction and/or discontinuation of the daily dose of IFN&#x003b1; given in patient CT, DK, and JS. One patient (EN) experienced numbness of fingers after 7&#x000a0;weeks of IFN&#x003b1; treatment. This disappeared after discontinuation of IFN&#x003b1; treatment and was previously described as a rare side effect of high-dose IFN&#x003b1; [<xref ref-type="bibr" rid="CR27">27</xref>]. One patient (CT) developed acral vasculitis with necrotic-like lesions in her fingertips without inflammatory cell infiltrate or microorganisms. Also a folliculitis-like inflammation of the skin was seen after the first infusion of the second treatment cycle. Skin biopsies were taken, and since a role of T cells could not be completely ruled out, the therapy was discontinued. One responding patient (DK) experienced grade 1 vitiligo. All serious adverse events are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> of the on-line available supplementary materials.</p><p>Five out of ten patients showed grade 2 IFN&#x003b1;-induced leucopenia, and six patients had leukocyte counts below 4&#x000a0;&#x000d7;&#x000a0;10e<sup>9</sup>&#x000a0;c/l at the start of T-cell infusions (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). The leukocyte numbers usually remained reduced throughout the full period that IFN&#x003b1; was administered and returned to pretreatment values after cessation of IFN&#x003b1; injections. Importantly, the absolute leukocyte count dropped below the normal number of leukocytes (4&#x000a0;&#x000d7;&#x000a0;10e<sup>9</sup>/l) in all patients which showed a clinical response, whereas it remained within the normal range of leukocytes 4&#x02013;12&#x000a0;&#x000d7;&#x000a0;10e<sup>9</sup>/L in 4 of the 5 non-responding patients (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c) resulting in a significantly lower number of leukocytes in responder patients compared to non-responder patients (<italic>P</italic>&#x000a0;=&#x000a0;0,016). Differential blood counts showed that especially neutrophil (42% reduction, range 0&#x02013;89%) and to a lesser extend lymphocyte numbers (29% reduction, range 2&#x02013;56%) were decreased after IFN&#x003b1; treatment and the percentage reduction of the neutrophil counts correlated with prolonged survival (<italic>P</italic>&#x000a0;=&#x000a0;0.022; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d). Neutrophil counts prior to IFN&#x003b1; treatment did not significantly differ between responder and non-responder patients (6.9 vs. 4.1&#x000a0;&#x000d7;&#x000a0;10e<sup>9</sup>/l, <italic>P</italic>&#x000a0;=&#x000a0;0.15).</p></sec><sec id="Sec13"><title>The tumor-reactive T cells in the group of clinical responders display a strong in vitro expansion rate</title><p>PBMC were stimulated 4 times with autologous tumor cells in vitro. The number of T cells obtained for each patient differed and ranged from 5.9 to 465&#x000a0;&#x000d7;&#x000a0;10<sup>7</sup>, reflecting a 2.1&#x02013;70-fold increase in cell number.</p><p>A comparison of the weekly expansion of T cells of the groups of responder and non-responder patients clearly revealed that tumor-stimulated PBMC of the clinical responders expanded faster than those of the non-responders, albeit not quite significant (<italic>P</italic>&#x000a0;=&#x000a0;0.056; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Indeed many more MLTC&#x02019;s were required to obtain sufficient numbers of cells to transfuse the non-clinical responders.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Proliferation of T cells during MLTC. T cells were produced by MLTC using autologous tumor cells as stimulator cells at day 0 and every week thereafter. The proliferation was assessed weekly after harvesting and counting of viable cell numbers using trypan blue. The proliferation rate is expressed as fold expansion of cells compared to cell number at day 0. The median and 25th percentile deviation of the weekly proliferation rate of responding (<italic>filled circle</italic>, <italic>n</italic>&#x000a0;=&#x000a0;5) and non-responding (<italic>open circle</italic>, <italic>n</italic>&#x000a0;=&#x000a0;5) patients are depicted</p></caption><graphic xlink:href="262_2011_1004_Fig2_HTML" id="MO2"/></fig></p><p>The differences in expansion were not associated with the level of HLA class I or II surface expression or the pattern of melanoma antigens expressed by the melanoma cells (data not shown).</p></sec><sec id="Sec14"><title>Characteristics of infused T cells</title><p>All T-cell batches were shown to consist mainly of CD3+CD4+ and CD3+CD8+ T cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) but the ratio of CD8+/CD4+ T cells varied considerably between patients. The majority of the T cells were CD45RA, CD62L, and CCR7 negative (effector memory T cells; data not shown). T-cell batches from patient DK, GM, HL, and JS showed expansion of CD3+CD4+ T cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). T-cell batches from three of these patients (responder patient DK and non-responder patients HL and JS) contained a relatively high-frequency CD4+CD25+FoxP3+ T cells, respectively, 9, 6, and 23%, whereas all other batches contained a mean of only 2.6&#x000a0;&#x000b1;&#x000a0;1.7% of CD4+CD25+FoxP3+ T cells (data not shown). Furthermore, while in all other patients, the percentage of CD3+CD8+CD56+ T cells was low (median 1%, range 0&#x02013;8%), this was the main subset present in the T-cell batch of patient CT (not shown).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Activation of infused T cells. T-cell batches were stimulated with autologous tumor cells and stained for phenotypic and activation markers as described in the Methods section. The percentage CD4+ and CD8+ T cells are given in the squares on the left of each plot. The CD154+CD4+ and CD137+CD8+ T cells (gated on CD3+ cells) are plotted, and percentages of tumor-specific activated cells (i.e., at least three times the medium control, see Fig.&#x000a0;1 of the on-line available supplementary materials) are given in the plots. The best overall clinical response of the individual patients is given in brackets behind the patient ID</p></caption><graphic xlink:href="262_2011_1004_Fig3_HTML" id="MO3"/></fig></p><p>On average, the T-cell batches induced 19% specific tumor cell lysis in a <sup>51</sup>Cr-cytotoxicity assay (at an effector to target ratio of 30 and after subtraction of autologous B-LCL/PHA-blasts lysis) and did not significantly differ between T cells administered to responding and non-responding patient (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). T cells from patient DK and JS contained mainly CD3+CD4+ T cells and did not show specific lysis in a short-term cytotoxicity assay, but specifically released IFN&#x003b3; upon stimulation with the patients&#x02019; tumor cells and not when stimulated with EBV-LCL or PHA blasts (data not shown).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Reactivity of infused T cells. The specific reactivity of the T-cell batches was analyzed by cytotoxicity assay. Effector T cells were added in increasing ratios to radioactively <sup>51</sup>Cr-labeled target cells (E/T) and incubated for 4&#x000a0;h at 37&#x000b0;C. Specific lysis of target cells was calculated after measuring the <sup>51</sup>Cr release as described [<xref ref-type="bibr" rid="CR22">22</xref>]. The percentage-specific lysis of autologous melanoma cells (<italic>black bars</italic>) and corresponding PHA blasts or EBV-LCL control cells (<italic>white bars</italic>) at different E/T ratios is depicted. The patient ID of the different T-cell batches is given in the <italic>upper right</italic> corner of the corresponding graphs. Results for the responder and non-responder patients are shown in the <italic>left</italic> and <italic>right panels</italic>, respectively</p></caption><graphic xlink:href="262_2011_1004_Fig4_HTML" id="MO4"/></fig></p><p>Based on the tumor-induced expression of the T-cell activation markers CD154/CD137, the infused T-cell batches constituted a median of 27.6% (mean 29.3%, range 0&#x02013;61.1%) tumor-specific T cells comprising a median of 2.5% (range 0&#x02013;22.6) tumor-specific CD3+CD4+ T cells and 16.5% (range 0&#x02013;57.3%) tumor-specific CD3+CD8+ T cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Comparison of the tumor reactivity between the T-cell batches revealed that there was no significant difference (<italic>P</italic>&#x000a0;=&#x000a0;0.55) in frequencies of tumor-specific activated CD3+CD4+CD154+ or CD3+CD8+CD137+ T cells administered to responding or non-responding patients. Assessment of the polyclonality of the tumor-specific T-cell batches, operationally defined as the cohort of CD4+ or CD8+ T cells expressing the same TCRV&#x003b2;-chain within the population of tumor-activated CD154+ and/or CD137+ T cells, revealed on average the involvement of 8 TCRV&#x003b2; families (range 0&#x02013;15) indicating that the infused tumor-specific T-cell population is highly polyclonal. No significant differences were observed in this respect between clinical responders and non-responders (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Polyclonality of tumor-reactive T cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient</th><th align="left" colspan="2">CD154+CD4+ T cells</th><th align="left" colspan="2">CD137+CD8+ T cells</th></tr><tr><th align="left">Subdominant</th><th align="left">Dominant</th><th align="left">Subdominant</th><th align="left">Dominant</th></tr></thead><tbody><tr><td align="left">AB (SD)</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">0</td></tr><tr><td align="left">BO (CR)</td><td char="." align="char">7</td><td char="." align="char">1</td><td char="." align="char">5</td><td char="." align="char">2</td></tr><tr><td align="left">CT (SD)</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">DK (PR)</td><td char="." align="char">8</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0</td></tr><tr><td align="left">EN (SD)</td><td char="." align="char">10</td><td char="." align="char">1</td><td char="." align="char">0</td><td char="." align="char">2</td></tr><tr><td align="left">FB (PD</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">GM (PD)</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">1</td></tr><tr><td align="left">HL (PD)</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="." align="char">5</td><td char="." align="char">2</td></tr><tr><td align="left">IV (PD)</td><td char="." align="char">1</td><td char="." align="char">3</td><td char="." align="char">2</td><td char="." align="char">0</td></tr><tr><td align="left">JS (PD)</td><td char="." align="char">8</td><td char="." align="char">1</td><td char="." align="char">0</td><td char="." align="char">0</td></tr></tbody></table><table-wrap-foot><p>T cells were stimulated overnight with autologous tumor cells, and the frequencies of cells expressing a specific TCRV&#x003b2; were analyzed in the populations of CD3+CD4+ and CD3+CD8+ T cells that expressed the activation marker CD154 or CD137, respectively. Frequencies of T cells that express a specific TCRV&#x003b2; were calculated after subtraction of background frequencies obtained with medium alone. The number of subdominant (frequency between 3 and 10%) and dominant (frequency &#x0003e;10%) TCRV&#x003b2; families represented within the tumor-specific T-cell fraction is depicted</p><p>The best overall clinical response of the individual patients is given in brackets behind the patient ID</p></table-wrap-foot></table-wrap></p><p>The polyfunctionality of the tumor-specific T cells, defined by the percentage of cells secreting IFN&#x003b3; and/or IL-2 within the fraction of tumor-specific T cells (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> of the supplementary materials available on-line), was not overtly different between the T-cell batches from the groups of clinically responding and non-responding patients. However, the cytokine profile produced by the infused T cells varied from predominantly Th1-type cytokines (IFN&#x003b3;, IL-2 and TNF&#x003b1;) in four clinically responding patients to predominantly Th2 cytokines (IL-4, IL-5 and IL-10, patient IV and JS), a mix of Th1 and Th2 cytokines (patient HL) or no cytokines at all (patient FB and GM) in patients without a clinical response (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). All together these data suggest that a predominant Th1 cytokine profile is beneficial for the clinical outcome.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Th1 and Th2 cytokine profile of T cells used for infusion. T cells were stimulated with autologous tumor cells overnight, and the supernatant was analyzed for the production of Th1 (IFN&#x003b3;, IL-2 and TNF&#x003b1;) and Th2 (IL-10, 4 and 5) cytokines. The cytokine production after subtraction of background production after culture in medium alone is depicted for responder (<italic>black bars</italic>) and non-responder (<italic>white bars</italic>) patients, respectively. The best overall clinical response of the individual patients is given in brackets behind the patient ID. <italic>ND</italic> is not detectable</p></caption><graphic xlink:href="262_2011_1004_Fig5_HTML" id="MO5"/></fig></p></sec></sec><sec id="Sec15"><title>Discussion</title><p>The results of this phase I/II study clearly demonstrate that adoptive transfer of PBMC-derived tumor-specific T cells in combination with low-dose INF&#x003b1; is feasible and safe and can induce a disease control (CR, PR, and SD) in 50% of the treated patients displaying progressive metastatic melanoma before treatment without any major adverse events related to the infusion of T cells. Analyses of several different immune-related parameters, which are discussed in more detail below, resulted in a number of hypotheses that could explain clinical reactivity or the lack thereof. All together, these data warrant the conduct of a controlled clinical trial to confirm or reject our current observations.</p><p>All responding patients experienced an IFN&#x003b1; -induced mild and transient leucopenia including both reduced lymphocyte and in particular neutrophil numbers. Interestingly, high peripheral neutrophil numbers are described to be an independent prognostic factor for worse outcome of IL-2-based therapy in melanoma patients [<xref ref-type="bibr" rid="CR28">28</xref>]. Here, we observe that the level of neutrophil reduction after IFN&#x003b1;-conditioning correlates with increased survival and that all clinically responding patients display a clear reduction in peripheral neutrophil numbers after IFN&#x003b1; treatment. Notably, there was no difference in neutrophil numbers between these groups before treatment that could explain a difference in survival. Since expansion of IL-10-secreting immunosuppressive neutrophils has recently been shown to correlate with disease progression in melanoma [<xref ref-type="bibr" rid="CR29">29</xref>], the observed IFN&#x003b1;-mediated reduction in neutrophil numbers may have resulted in lower IL-10 levels but unfortunately this could not be tested in our current patient group because we did not obtain serum of all patients prior to therapy. A recent study in melanoma patients reported the reduction in regulatory T cells (Treg) following high-dose IFN&#x003b1; treatment [<xref ref-type="bibr" rid="CR30">30</xref>]. Whether the leucopenia observed in our study after a much lower dose of IFN&#x003b1; treatment also reduces the frequency of Treg or creates space for infused T cells and/or induces homeostatic cytokines IL-7 and IL-15, as has been suggested as mechanism to explain the beneficial effect of other lymphodepleting-conditioning regimens [<xref ref-type="bibr" rid="CR2">2</xref>], remains to be elucidated. Although IFN&#x003b1; is a pleiotropic cytokine and its use may contribute to the eventual clinical effect via a variety of pathways, a direct inhibitory effect of IFN&#x003b1; on the tumor is unlikely since single-agent IFN&#x003b1; treatment is only effective in much higher doses than the low dose used in our study, which was proven to be not effective in phase I/II studies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p>To unravel potential mechanisms underlying the clinical responsiveness of patients, we performed a detailed characterization of the infused T-cell batches and observed that the expansion rate of T cells during the production phase was higher for cells infused in patients with a clinical response. This cannot be attributed to a reduced frequency of tumor-specific T cells in the PBMC or lack of antigen expression on autologous cell lines used to obtain the T-cell batches, since tumor-specific polyclonal T-cell populations were obtained in all patients. Whether the reduced expansion rate of T cells infused to non-responding patients is due to expression and/or secretion of immunosuppressive factors by their autologous tumor cells is subject of our current investigations. Alternatively, the reduced proliferation in the non-responding patients may be due to an intrinsic lack of proliferative capacity of their PBMC. Indeed, the proliferative capacity of ex vivo expanded tumor-infiltrating lymphocytes has been associated with tumor regression and has been linked to telomere length in these T cells [<xref ref-type="bibr" rid="CR33">33</xref>]. The reduced proliferation of T cells may also be due to the selective expansion of Treg, since at least in some cases (patient HL and JS), relatively high frequencies of CD4+CD25+FoxP3+ T cells were detected in the T-cell batches. Indeed, the accumulation of Treg in peripheral blood and locally in the tumor environment and metastatic lymph nodes of melanoma patients has previously been associated with impaired T-cell responsiveness [<xref ref-type="bibr" rid="CR34">34</xref>] and as such supports this idea. However, functional studies are required to appreciate their suppressive role during the mixed tumor T-cell cultures in vitro.</p><p>The stimulation of patients&#x02019; PBMC with autologous tumor cells, expressing the full spectrum of relevant HLA molecules and tumor antigens, leads to expansion of polyclonal CD4+ as well as CD8+ T cells, which may contribute to the current success. Although a recent case report shows that treatment of a melanoma patient with clonal NY-ESO-1-specific CD4+ T cells can be successful [<xref ref-type="bibr" rid="CR35">35</xref>], we aim at infusion of polyclonal T cells, thus preventing the appearance of antigen-loss variants frequently found after transfer of single-antigen-specific T cells [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Since polyclonal tumor-reactive T cells are infused in all patients but the clinical response does not merely correlate to the percentage or ratio of specific CD8+ versus CD4+ T cells, we conclude that the presence of a broad repertoire of tumor-reactive T cells by itself is not sufficient to induce a clinical effect but relies on other factors including their functional activity. Our patient number is too small to reach significance, but our results are in line with previous observations [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>], indicating that infusion of T cells that predominantly produce Th1 cytokines results in a better clinical outcome compared to infusion of T cells that produce mainly Th2 cytokines or no Th1/Th2 cytokines at all and that the presence of both tumor-specific Th1 cells and CTL mediates an effective anti-tumor response [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p>In summary, the adoptive transfer of polyclonal tumor-specific T cells obtained after stimulation of PBMC with autologous tumor cells in combination with low-dose IFN&#x003b1; can result in durable clinical responses in stage IV melanoma patients supporting the idea to explore IFN&#x003b1; as an alternative conditioning regimen and cytokine for ACT trials. Although the use of IFN&#x003b1; also comes with some side effects, including the beneficial leukopenia and controllable psychological symptoms, it is far less toxic than high-dose IL-2, commonly used to support transferred T cells. The clinical responses reported here are associated with IFN&#x003b1;-induced lympho- and neutropenia and the proliferative capacity as well as the Th1/Th2 cytokine profile of the T cells used for infusion, underscoring the importance of measuring parameters that are associated with clinical reactivity of the infused T-cell batches to fully appreciate their in vivo effectiveness. Eventual combination of this approach with other treatment options may even further enhance the clinical outcome. One possibility is the combined use of ACT/IFN&#x003b1; with ipilimumab or negative immunoregulatory human cell surface receptor PD-1 (programmed death-1). These immune activating antibodies may result in further in vivo expansion of tumor-specific T cells and improved clinical effect after ACT/IFN&#x003b1;.</p></sec><sec sec-type="supplementary-material"><sec id="AppESM1"><title>Electronic supplementary material</title><supplementary-material id="d28e1449" content-type="local-data"><p>Below is the link to the electronic supplementary material.
</p><media xlink:href="262_2011_1004_MOESM1_ESM.pdf" id="MOESM1" mimetype="application" mime-subtype="pdf"><caption><p>Supplementary material 1 (PDF 47 kb)</p></caption></media></supplementary-material></sec></sec></body><back><ack><p>The authors wish to thank Dr. Els Persijn-van Meerten for experienced evaluation of CT and MRI scans and Prof. Hein Putter for statistical evaluation of the data. We also want to thank Conny Hoogstraten, Hannah Wensink, Inonge van Twillert and Loes van Eijk for their technical assistance.</p><p><bold>Conflict of interest</bold> The authors declare that they have no conflict of interest.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oble</surname><given-names>DA</given-names></name><name><surname>Loewe</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names><suffix>Jr</suffix></name></person-group><article-title>Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma</article-title><source>Cancer Immun</source><year>2009</year><volume>9</volume><fpage>3</fpage><pub-id pub-id-type="pmid">19338264</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Sherry</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>MS</given-names></name><name><surname>Royal</surname><given-names>R</given-names></name><name><surname>Kammula</surname><given-names>U</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Citrin</surname><given-names>DE</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name><name><surname>Wunderlich</surname><given-names>J</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Thomasian</surname><given-names>A</given-names></name><name><surname>Downey</surname><given-names>SG</given-names></name><name><surname>Smith</surname><given-names>FO</given-names></name><name><surname>Klapper</surname><given-names>J</given-names></name><name><surname>Morton</surname><given-names>K</given-names></name><name><surname>Laurencot</surname><given-names>C</given-names></name><name><surname>White</surname><given-names>DE</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>5233</fpage><lpage>5239</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.16.5449</pub-id><pub-id pub-id-type="pmid">18809613</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Adoptive cell transfer therapy</article-title><source>Semin Oncol</source><year>2007</year><volume>34</volume><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2007.09.002</pub-id><pub-id pub-id-type="pmid">18083376</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posthuma</surname><given-names>EF</given-names></name><name><surname>Marijt</surname><given-names>EW</given-names></name><name><surname>Barge</surname><given-names>RM</given-names></name><name><surname>Soest</surname><given-names>RA</given-names></name><name><surname>Baas</surname><given-names>IO</given-names></name><name><surname>Starrenburg</surname><given-names>CW</given-names></name><name><surname>Zelderen-Bhola</surname><given-names>SL</given-names></name><name><surname>Fibbe</surname><given-names>WE</given-names></name><name><surname>Smit</surname><given-names>WM</given-names></name><name><surname>Willemze</surname><given-names>R</given-names></name><name><surname>Falkenburg</surname><given-names>JH</given-names></name></person-group><article-title>Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease</article-title><source>Biol Blood Marrow Transplant</source><year>2004</year><volume>10</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2003.11.003</pub-id><pub-id pub-id-type="pmid">14993886</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cangemi</surname><given-names>G</given-names></name><name><surname>Morandi</surname><given-names>B</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>A</given-names></name><name><surname>Peri</surname><given-names>C</given-names></name><name><surname>Conte</surname><given-names>R</given-names></name><name><surname>Damonte</surname><given-names>G</given-names></name><name><surname>Ferlazzo</surname><given-names>G</given-names></name><name><surname>Biassoni</surname><given-names>R</given-names></name><name><surname>Melioli</surname><given-names>G</given-names></name></person-group><article-title>IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome</article-title><source>Int Immunol</source><year>2003</year><volume>15</volume><fpage>1415</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxg140</pub-id><pub-id pub-id-type="pmid">14645150</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>R</given-names></name><name><surname>Aptsiauri</surname><given-names>N</given-names></name><name><surname>Del</surname><given-names>CA</given-names></name><name><surname>Maleno</surname><given-names>I</given-names></name><name><surname>Cabrera</surname><given-names>T</given-names></name><name><surname>Ruiz-Cabello</surname><given-names>F</given-names></name><name><surname>Garrido</surname><given-names>F</given-names></name><name><surname>Garcia-Lora</surname><given-names>A</given-names></name></person-group><article-title>HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>1507</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1007/s00262-009-0701-z</pub-id><pub-id pub-id-type="pmid">19340423</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gigante</surname><given-names>M</given-names></name><name><surname>Blasi</surname><given-names>A</given-names></name><name><surname>Loverre</surname><given-names>A</given-names></name><name><surname>Mancini</surname><given-names>V</given-names></name><name><surname>Battaglia</surname><given-names>M</given-names></name><name><surname>Selvaggi</surname><given-names>FP</given-names></name><name><surname>Maiorano</surname><given-names>E</given-names></name><name><surname>Napoli</surname><given-names>A</given-names></name><name><surname>Castellano</surname><given-names>G</given-names></name><name><surname>Storkus</surname><given-names>WJ</given-names></name><name><surname>Gesualdo</surname><given-names>L</given-names></name><name><surname>Ranieri</surname><given-names>E</given-names></name></person-group><article-title>Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine</article-title><source>Mol Immunol</source><year>2009</year><volume>46</volume><fpage>893</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2008.09.015</pub-id><pub-id pub-id-type="pmid">19041139</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>HJ</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name><name><surname>Cole</surname><given-names>AG</given-names></name><name><surname>Schatzle</surname><given-names>JD</given-names></name><name><surname>Forman</surname><given-names>J</given-names></name><name><surname>Farrar</surname><given-names>JD</given-names></name></person-group><article-title>Reciprocal responsiveness to IL-12 and IFN-{alpha} specifies human CD8+ effector versus central memory T cell fates</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>5516</fpage><lpage>5525</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-11-188458</pub-id><pub-id pub-id-type="pmid">19299334</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouquie</surname><given-names>R</given-names></name><name><surname>Bonnin</surname><given-names>A</given-names></name><name><surname>Bernardeau</surname><given-names>K</given-names></name><name><surname>Khammari</surname><given-names>A</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Jotereau</surname><given-names>F</given-names></name><name><surname>Labarriere</surname><given-names>N</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name></person-group><article-title>A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>553</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0578-2</pub-id><pub-id pub-id-type="pmid">18751701</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinrichs</surname><given-names>CS</given-names></name><name><surname>Spolski</surname><given-names>R</given-names></name><name><surname>Paulos</surname><given-names>CM</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Kerstann</surname><given-names>KW</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Klebanoff</surname><given-names>CA</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>5326</fpage><lpage>5333</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-09-113050</pub-id><pub-id pub-id-type="pmid">18276844</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchida</surname><given-names>Y</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name></person-group><article-title>Response evaluation criteria in solid tumors (RECIST): new guidelines</article-title><source>Med Pediatr Oncol</source><year>2001</year><volume>37</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1002/mpo.1154</pub-id><pub-id pub-id-type="pmid">11466715</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>O&#x02019;Day</surname><given-names>S</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Binder</surname><given-names>M</given-names></name><name><surname>Bohnsack</surname><given-names>O</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name><name><surname>Humphrey</surname><given-names>R</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name></person-group><article-title>Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>7412</fpage><lpage>7420</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1624</pub-id><pub-id pub-id-type="pmid">19934295</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwenstijn</surname><given-names>N</given-names></name><name><surname>Slager</surname><given-names>EH</given-names></name><name><surname>Bakker</surname><given-names>AB</given-names></name><name><surname>Schreurs</surname><given-names>MW</given-names></name><name><surname>Spek</surname><given-names>CW</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Schrier</surname><given-names>PI</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage</article-title><source>Br J Cancer</source><year>1997</year><volume>76</volume><fpage>1562</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1038/bjc.1997.597</pub-id><pub-id pub-id-type="pmid">9413942</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Boer</surname><given-names>AJ</given-names></name><name><surname>Vogel</surname><given-names>AM</given-names></name><name><surname>Loenen</surname><given-names>WA</given-names></name><name><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Molecular characterization of the melanocyte lineage-specific antigen gp100</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>20126</fpage><lpage>20133</lpage><pub-id pub-id-type="pmid">7519602</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brasseur</surname><given-names>F</given-names></name><name><surname>Marchand</surname><given-names>M</given-names></name><name><surname>Vanwijck</surname><given-names>R</given-names></name><name><surname>Herin</surname><given-names>M</given-names></name><name><surname>Lethe</surname><given-names>B</given-names></name><name><surname>Chomez</surname><given-names>P</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name></person-group><article-title>Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors [letter]</article-title><source>Int J Cancer</source><year>1992</year><volume>52</volume><fpage>839</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910520528</pub-id><pub-id pub-id-type="pmid">1428237</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plaen</surname><given-names>E</given-names></name><name><surname>Arden</surname><given-names>K</given-names></name><name><surname>Traversari</surname><given-names>C</given-names></name><name><surname>Gaforio</surname><given-names>JJ</given-names></name><name><surname>Szikora</surname><given-names>JP</given-names></name><name><surname>De</surname><given-names>SC</given-names></name><name><surname>Brasseur</surname><given-names>F</given-names></name><name><surname>Bruggen</surname><given-names>P</given-names></name><name><surname>Lethe</surname><given-names>B</given-names></name><name><surname>Lurquin</surname><given-names>C</given-names></name></person-group><article-title>Structure, chromosomal localization, and expression of 12 genes of the MAGE family</article-title><source>Immunogenetics</source><year>1994</year><volume>40</volume><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/BF01246677</pub-id><pub-id pub-id-type="pmid">7927540</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takase</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>CR</given-names></name><name><surname>Mahdi</surname><given-names>RM</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Dirusso</surname><given-names>GB</given-names></name><name><surname>Midgley</surname><given-names>FM</given-names></name><name><surname>Dogra</surname><given-names>R</given-names></name><name><surname>Allende</surname><given-names>G</given-names></name><name><surname>Rosenkranz</surname><given-names>E</given-names></name><name><surname>Pugliese</surname><given-names>A</given-names></name><name><surname>Egwuagu</surname><given-names>CE</given-names></name><name><surname>Gery</surname><given-names>I</given-names></name></person-group><article-title>Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals</article-title><source>Int Immunol</source><year>2005</year><volume>17</volume><fpage>1131</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh275</pub-id><pub-id pub-id-type="pmid">16030131</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarnoudse</surname><given-names>CA</given-names></name><name><surname>Doel</surname><given-names>PB</given-names></name><name><surname>Heemskerk</surname><given-names>B</given-names></name><name><surname>Schrier</surname><given-names>PI</given-names></name></person-group><article-title>Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1</article-title><source>Int J Cancer</source><year>1999</year><volume>82</volume><fpage>442</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19990730)82:3&#x0003c;442::AID-IJC19&#x0003e;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">10399963</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Lethe</surname><given-names>B</given-names></name><name><surname>Lehmann</surname><given-names>F</given-names></name><name><surname>Baren</surname><given-names>N</given-names></name><name><surname>Baurain</surname><given-names>JF</given-names></name><name><surname>Smet</surname><given-names>C</given-names></name><name><surname>Chambost</surname><given-names>H</given-names></name><name><surname>Vitale</surname><given-names>M</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>Coulie</surname><given-names>PG</given-names></name></person-group><article-title>Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor</article-title><source>Immunity</source><year>1997</year><volume>6</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80426-4</pub-id><pub-id pub-id-type="pmid">9047241</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godet</surname><given-names>Y</given-names></name><name><surname>Moreau-Aubry</surname><given-names>A</given-names></name><name><surname>Guilloux</surname><given-names>Y</given-names></name><name><surname>Vignard</surname><given-names>V</given-names></name><name><surname>Khammari</surname><given-names>A</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Jotereau</surname><given-names>F</given-names></name><name><surname>Labarriere</surname><given-names>N</given-names></name></person-group><article-title>MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2673</fpage><lpage>2682</lpage><pub-id pub-id-type="doi">10.1084/jem.20081356</pub-id><pub-id pub-id-type="pmid">18936238</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herin</surname><given-names>M</given-names></name><name><surname>Lemoine</surname><given-names>C</given-names></name><name><surname>Weynants</surname><given-names>P</given-names></name><name><surname>Vessiere</surname><given-names>F</given-names></name><name><surname>Pel</surname><given-names>A</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>Devos</surname><given-names>R</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name></person-group><article-title>Production of stable cytolytic T-cell clones directed against autologous human melanoma</article-title><source>Int J Cancer</source><year>1987</year><volume>39</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910390320</pub-id><pub-id pub-id-type="pmid">3493226</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdegaal</surname><given-names>EME</given-names></name><name><surname>Huinink</surname><given-names>DB</given-names></name><name><surname>Hoogstraten</surname><given-names>C</given-names></name><name><surname>Marijnissen</surname><given-names>AK</given-names></name><name><surname>Gorsira</surname><given-names>MB</given-names></name><name><surname>Claas</surname><given-names>FH</given-names></name><name><surname>Osanto</surname><given-names>S</given-names></name></person-group><article-title>Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient</article-title><source>Hum Immunol</source><year>1999</year><volume>60</volume><fpage>1195</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1016/S0198-8859(99)00124-X</pub-id><pub-id pub-id-type="pmid">10626733</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besser</surname><given-names>MJ</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name><surname>Treves</surname><given-names>AJ</given-names></name><name><surname>Zippel</surname><given-names>D</given-names></name><name><surname>Itzhaki</surname><given-names>O</given-names></name><name><surname>Hershkovitz</surname><given-names>L</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kubi</surname><given-names>A</given-names></name><name><surname>Hovav</surname><given-names>E</given-names></name><name><surname>Chermoshniuk</surname><given-names>N</given-names></name><name><surname>Shalmon</surname><given-names>B</given-names></name><name><surname>Hardan</surname><given-names>I</given-names></name><name><surname>Catane</surname><given-names>R</given-names></name><name><surname>Markel</surname><given-names>G</given-names></name><name><surname>Apter</surname><given-names>S</given-names></name><name><surname>Ben-Nun</surname><given-names>A</given-names></name><name><surname>Kuchuk</surname><given-names>I</given-names></name><name><surname>Shimoni</surname><given-names>A</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name></person-group><article-title>Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>2646</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0041</pub-id><pub-id pub-id-type="pmid">20406835</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speetjens</surname><given-names>FM</given-names></name><name><surname>Kuppen</surname><given-names>PJ</given-names></name><name><surname>Welters</surname><given-names>MJ</given-names></name><name><surname>Essahsah</surname><given-names>F</given-names></name><name><surname>Voet van den Brink</surname><given-names>AM</given-names></name><name><surname>Lantrua</surname><given-names>MG</given-names></name><name><surname>Valentijn</surname><given-names>AR</given-names></name><name><surname>Oostendorp</surname><given-names>J</given-names></name><name><surname>Fathers</surname><given-names>LM</given-names></name><name><surname>Nijman</surname><given-names>HW</given-names></name><name><surname>Drijfhout</surname><given-names>JW</given-names></name><name><surname>Velde</surname><given-names>CJ</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Burg</surname><given-names>SH</given-names></name></person-group><article-title>Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>1086</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2227</pub-id><pub-id pub-id-type="pmid">19188184</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">de Vos-van Steenwijk PJ, Heusinkveld M, Ramwadhdoeb&#x000e9; TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH (2010) An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 70:2707&#x02013;2717</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jong</surname><given-names>A</given-names></name><name><surname>Poelgeest</surname><given-names>MI</given-names></name><name><surname>Hulst</surname><given-names>JM</given-names></name><name><surname>Drijfhout</surname><given-names>JW</given-names></name><name><surname>Fleuren</surname><given-names>GJ</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Kenter</surname><given-names>G</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Burg</surname><given-names>SH</given-names></name></person-group><article-title>Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>5449</fpage><lpage>5455</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0831</pub-id><pub-id pub-id-type="pmid">15289354</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>T</given-names></name></person-group><article-title>Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients</article-title><source>Cancer</source><year>1986</year><volume>57</volume><fpage>1705</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19860415)57:8+&#x0003c;1705::AID-CNCR2820571314&#x0003e;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">3948142</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Suciu</surname><given-names>S</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Kruit</surname><given-names>W</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Lienard</surname><given-names>D</given-names></name><name><surname>von der</surname><given-names>MH</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1562</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.0274</pub-id><pub-id pub-id-type="pmid">17443000</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santo</surname><given-names>C</given-names></name><name><surname>Arscott</surname><given-names>R</given-names></name><name><surname>Booth</surname><given-names>S</given-names></name><name><surname>Karydis</surname><given-names>I</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Asher</surname><given-names>R</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Middleton</surname><given-names>M</given-names></name><name><surname>Cerundolo</surname><given-names>V</given-names></name></person-group><article-title>Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A</article-title><source>Nat Immunol</source><year>2010</year><volume>11</volume><fpage>1039</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1038/ni.1942</pub-id><pub-id pub-id-type="pmid">20890286</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Napolitano</surname><given-names>M</given-names></name><name><surname>Celentano</surname><given-names>E</given-names></name><name><surname>Simeone</surname><given-names>E</given-names></name><name><surname>Gentilcore</surname><given-names>G</given-names></name><name><surname>Daponte</surname><given-names>A</given-names></name><name><surname>Capone</surname><given-names>M</given-names></name><name><surname>Caraco</surname><given-names>C</given-names></name><name><surname>Calemma</surname><given-names>R</given-names></name><name><surname>Beneduce</surname><given-names>G</given-names></name><name><surname>Cerrone</surname><given-names>M</given-names></name><name><surname>Rosa</surname><given-names>V</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Castello</surname><given-names>G</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Mozzillo</surname><given-names>N</given-names></name></person-group><article-title>Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment</article-title><source>J. Transl Med</source><year>2010</year><volume>8</volume><fpage>76</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1186/1479-5876-8-76</pub-id><pub-id pub-id-type="pmid">20712892</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lens</surname><given-names>MB</given-names></name><name><surname>Dawes</surname><given-names>M</given-names></name></person-group><article-title>Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>1818</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.07.070</pub-id><pub-id pub-id-type="pmid">11919239</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name></person-group><article-title>Interferons in melanoma</article-title><source>Curr Opin Oncol</source><year>1996</year><volume>8</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1097/00001622-199603000-00015</pub-id><pub-id pub-id-type="pmid">8727310</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hodes</surname><given-names>RJ</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name></person-group><article-title>Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>7046</fpage><lpage>7052</lpage><pub-id pub-id-type="pmid">16272366</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correll</surname><given-names>A</given-names></name><name><surname>Tuettenberg</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Jonuleit</surname><given-names>H</given-names></name></person-group><article-title>Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination</article-title><source>Exp Dermatol</source><year>2010</year><volume>19</volume><fpage>e213</fpage><lpage>e221</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2009.01055.x</pub-id><pub-id pub-id-type="pmid">20500773</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunder</surname><given-names>NN</given-names></name><name><surname>Wallen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Hendricks</surname><given-names>DW</given-names></name><name><surname>Reilly</surname><given-names>JZ</given-names></name><name><surname>Rodmyre</surname><given-names>R</given-names></name><name><surname>Jungbluth</surname><given-names>A</given-names></name><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name></person-group><article-title>Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1</article-title><source>N Eng J Med</source><year>2008</year><volume>358</volume><fpage>2698</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0800251</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackensen</surname><given-names>A</given-names></name><name><surname>Meidenbauer</surname><given-names>N</given-names></name><name><surname>Vogl</surname><given-names>S</given-names></name><name><surname>Laumer</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Andreesen</surname><given-names>R</given-names></name></person-group><article-title>Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>5060</fpage><lpage>5069</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.1100</pub-id><pub-id pub-id-type="pmid">17075125</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Economou</surname><given-names>JS</given-names></name><name><surname>Donahue</surname><given-names>TR</given-names></name><name><surname>la</surname><given-names>RP</given-names></name><name><surname>Morris</surname><given-names>LF</given-names></name><name><surname>Jalil</surname><given-names>J</given-names></name><name><surname>Dissette</surname><given-names>VB</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Glaspy</surname><given-names>JA</given-names></name><name><surname>Gomez-Navarro</surname><given-names>J</given-names></name><name><surname>Cochran</surname><given-names>AJ</given-names></name></person-group><article-title>Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>390</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0783</pub-id><pub-id pub-id-type="pmid">19118070</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>Cancer immunotherapy</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1072</fpage><pub-id pub-id-type="doi">10.1056/NEJMc081511</pub-id><pub-id pub-id-type="pmid">18768956</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddell</surname><given-names>SR</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Principles for adoptive T cell therapy of human viral diseases</article-title><source>Annu Rev Immunol</source><year>1995</year><volume>13</volume><fpage>545</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.13.040195.002553</pub-id><pub-id pub-id-type="pmid">7612234</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>D</given-names></name><name><surname>Ismail</surname><given-names>N</given-names></name><name><surname>Kroeger</surname><given-names>D</given-names></name><name><surname>Rudulier</surname><given-names>C</given-names></name><name><surname>Bretscher</surname><given-names>P</given-names></name></person-group><article-title>Macroimmunology and immunotherapy of cancer</article-title><source>Immunotherapy</source><year>2009</year><volume>1</volume><fpage>367</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.2217/imt.09.6</pub-id><pub-id pub-id-type="pmid">20635957</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name></person-group><article-title>CD4+ T lymphocytes: a critical component of antitumor immunity</article-title><source>Cancer Invest</source><year>2005</year><volume>23</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">16193641</pub-id></mixed-citation></ref></ref-list></back></article>